DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 3 Eli Lilly's - 3 — - 2 Lilly - 2 Zepbound - 1 Patrik Jonsson - 1 Jonsson - 1 Leonard Glass - 1
Top related locs:
U.S Orlando , Florida Provo , Utah United States Bristol Indianapolis , Indiana
Top related orgs:
FDA - 3 CNBC - 2 Food and Drug Administration - 1 Diabetes - 1 OSA - 1 Novo Nordisk - 1 Pharmacy - 1 Food - 1

Search resuls for: "Eli Lilly Diabetes"


3 mentions found


☆ Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
  + stars: | 2024-06-21 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +5 min
Eli Lilly presented the new data from the trials at the American Diabetes Association's 84th Scientific Sessions in Orlando, Florida, on Friday. An estimated 80 million patients in the U.S. experience the disease, Eli Lilly said in a press release. Disease resolution for OSA is defined as a patient having fewer than five AHI events per hour, according to Eli Lilly. Eli Lilly on Friday reiterated that Zepbound met the main goal of the trial, which was reducing AHI events. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity.
Persons: Eli Lilly, Zepbound, Patrik Jonsson, Jonsson, Leonard Glass, —, Eli Lilly's Organizations: Food and Drug Administration, Diabetes, CNBC, OSA, FDA Locations: Orlando , Florida, U.S
☆ FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
  + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +6 min
George Frey | ReutersThe Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The FDA said the approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average. The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Preliminary data is already available: A recent late-stage trial found that Novo Nordisk's weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%.
Persons: George Frey, Eli Lilly, John Sharretts, Eli Lilly's, Wegovy, Lilly, Mike Mason, Eli Lilly Diabetes Organizations: Novo Nordisk, Pharmacy, Reuters, Food, Drug Administration, U.S, FDA's Center, Drug, FDA, Obesity Locations: Provo , Utah, U.S, United States
☆ Medicare wants to cut the price on an Eli Lilly drug. What it means for LLY shares
  + stars: | 2023-08-30 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +8 min
Eli Lilly's revenue from Jardiance — which it markets alongside privately held German biotech firm Boehringer Ingelheim — is likely to suffer due to Medicare negotiations. Compared to those growth drivers, Jardiance is a minor character in the Eli Lilly investment story. However, the deceleration is not entirely due to likely lower realized prices from Medicare negotiations. Eli Lilly looks "relatively protected" from early Medicare negotiations, BMO's Seigmerman said. Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023.
Persons: Eli Lilly, Biden, Myers Squibb, Johnson, Eli Lilly's, —, Evan Seigerman, Seigerman, BMO's Seigmerman, Lilly, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: pharma, Myers, Club, Johnson, Medicare, donanemab, Bank of America, FactSet, Mounjaro, Merck, Constitution, Wall Street, Bristol Myers Squibb, BMO Capital, CNBC, Services, drugmakers, and Drug Administration, FDA, Trulicity, Bloomberg, Getty Locations: Bristol, U.S, Indianapolis , Indiana
0 next >>
Total: 3